There’s probably one last gap rally left in this stock in the .20-.40 range. It could be in 2022. The smartest thing the morons of Wakefield could do is sell the entire company for $150M. A highly reasonable price for a pharma to change IP and explore all asset indications. If they engaged with someone like Locust Walk, they could probably find a buyer in that range. I just don’t think Leo is smart enough to do such. He has the brains of a lowland ground animal, the integrity of a Madolf and the reputation of a con man. His creative writing team is in the same camp. The belief of the lab studies that they can’t let go of is rather pathetic. Morons.